Lorcaserin Hcl for the treatment of obesity

@article{Shukla2015LorcaserinHF,
  title={Lorcaserin Hcl for the treatment of obesity},
  author={Alpana P Shukla and R. Kumar and L. Aronne},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={2531 - 2538}
}
  • Alpana P Shukla, R. Kumar, L. Aronne
  • Published 2015
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Introduction: Obesity is a major health priority necessitating safe and effective strategies to address the obesity epidemic. Lorcaserin is a serotonergic agonist specific to the 5HT 2C receptor approved for chronic management of obesity in patients with a BMI ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with comorbidities related to obesity. Areas covered: In this paper, the pharmacodynamic and pharmacokinetic properties of lorcaserin are reviewed followed by a discussion of efficacy and safety data from… CONTINUE READING

    Paper Mentions

    European Guidelines for Obesity Management in Adults
    • 306
    • PDF
    Pharmacotherapy for obesity in individuals with type 2 diabetes
    • 10
    Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists
    • 7
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 44 REFERENCES
    Multicenter, placebo-controlled trial of lorcaserin for weight management.
    • 722
    • Highly Influential
    • PDF
    A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    • 346
    • Highly Influential
    • PDF
    A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
    • 681
    • PDF
    Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study
    • 444
    • Highly Influential
    • PDF
    Lorcaserin: A Review of its Use in Chronic Weight Management
    • 25